CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), David Lebwohl(Intellia Therapeutics (United States)), Andrew Schiermeier(University of Auckland), Jonathan A. Phillips(Boehringer Ingelheim (United States)), David E. Gutstein(Scripps Research Institute), Olivier Harari(Regeneron (United States)), Kristy Wood(University of Auckland), Michael L. Maitland(Virginia Cancer Institute), Randy Soltys(University of Auckland), Brian Zambrowicz(Regeneron (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Yuanxin Xu(Nanjing University of Chinese Medicine), Marianna Fontana(Amyloidosis Foundation), Adam Amaral(University of Auckland), Christos A. Kyratsous(Regeneron (United States)), Daniel J. O’Connell(Harvard University), Jörg Täubel(British Heart Foundation), Kathryn Walsh(University of Auckland), Mark D. McKee(University of Auckland), Adam P. Boyd(University of Auckland), Justin Kao(University of Auckland), Ed Gane(University of Auckland), John P. Leonard(Institute of Genetics), Andrew Murphy(University of Auckland), Jeffrey Cehelsky(Alnylam Pharmaceuticals (United States)), Jessica Seitzer(Intellia Therapeutics (United States))
Cited by 1,694
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k